PAD Profile : Denosumab - Osteoporosis

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Denosumab - Osteoporosis

PAD Profile : Denosumab - Osteoporosis

Keywords :

PSDs, patient specific directions, postmenopausal osteoporosis

Brand Names Include :

Prolia

Traffic Light Status

Status 1 of 1.

Status :

Green (see narrative)

Important

Formulations :

Subcutaneous injection (sc)

Important Information :

Patients with a CKD of 4 or 5 and patients with a T-score of < -4.5 to remain under specialist care.

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

NFD1

NICE

Comments :

No comments returned.

Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type

Document

Review Date

Guidelines (Local)

Osteoporosis Assessment and Treatment Guideline - Jun 2021

01 June 2024

NICE Technology Appraisal

NICE TA204 - Denosumab for postmenopausal osteoporosis

Information

Denosumab - Guidance during Covid 19 - June 2020.pdf

Information

Denosumab prescribing information - Updated July 2023

01 July 2026

Committee Recommendations

Date

Committee Name

Narrative

05 July 2023

Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed Denosumab Prescribing Information to support initiation and ongoing administration in primary care.

01 November 2017

Surrey Medicines Commissioners Group

Patient Specific Directions (PSDs) are often used to enable non-medical practitioners (practice nurses, health care assistants) to administer specific medicines for specific conditions. A PSD tempate for EMIS system users has been developed by a local GP practice to improve the consistency and content of their Denosumab PSDs. This PSD template (among others) is available from your local Medicines Management Team should your practice wish to adopt / adapt it. Please contact your local Medicines Management Team for assistance

01 November 2017

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Osteoporosis guidelines have been reviewed and updated. Denosumab has been included as a treatment option for postmenopausal women and men who are intolerant to two bisphosphonates / or have a contraindication to bisphosphonates. Certain patients should remain under the care of the secondary care clinicians and they include: Renal patients with a CKD of 4 or 5 and patients with a T score of <-4.5. The osteoporosis guidelines are supported by two algorithms (algorithm 1 - Treatment Pathway for adults; algorithm 2 - Review of Long-term Bisphosphonate Therapy) which have been extracted from the guideline and provided as separate documents (below) for ease of use.

Associated BNF Codes

06. Endocrine System

06.06.02. Bisphosphonates and other drugs